Company intelligence / Profile preview
CEOLIA Pharma
Chuo-ku, Tokyo, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
CEOLIA Pharma has obtained Japanese approval for ENT-103 (COMLEX OTIC SOLUTION 1.5%) for otic use after successful phase 3 trials achieving their primary endpoint; the company markets both approved drugs such as levofloxacin and metyrapone, and has established partnerships for new drug launches in otolaryngology.
- Therapeutic areas
- Infectious DiseasesEndocrinology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
NANO MRNA Co., Ltd. (co-development/launch, e.g. ENT-103)Takeda Pharmaceutical (direct sales agreement)Stallergenes Greer (marketing of Actair in Japan)
Beyond the preview
Go deeper on CEOLIA Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEOLIA Pharma.